I’m not sure if my algorithm is trying to tell me something, but lately my feeds are awash with people documenting their “bleph” journeys—shorthand for upper and lower blepharoplasty, the surgical fixes for sagging eyelids and stubborn dark circles. And it’s not just anecdotal: the latest audit from the British Association of Aesthetic Plastic Surgeons (BAAPS) shows blepharoplasty procedures rose by 13% between 2023 and 2024. On a global scale, eyelid surgery has cemented itself as one of the most in-demand aesthetic procedures, with 1.7 million performed worldwide last year—a striking 24% jump on the year before.
The surge doesn’t surprise me. I’ve never found non-surgical solutions for tired eyes to be convincing. Dermal fillers, for example, can help with tear-trough hollowing, but they only address certain concerns, and when used in such a delicate area, they come with a plethora of risks. Think vascular occlusion, long-lasting swelling and in the worst-case scenario, even blindness.
